Further lead optimization on N-acyl-triazolopiperazine antagonists to the neurokinin-3 receptor (NK 3 R) based on the concurrent improvement in bioactivity and ligand lipophilic efficiency (LLE) is reported. Overall, compound 3 (LLE > 6) emerged as the most efficacious in castrated rat and monkey to lower plasma LH, and it displayed the best off-target safety profile that led to its clinical candidate nomination for the treatment of sex-hormone disorders.
T he neurokinin-3 receptor (NK 3 R) is a class A GPCR with neurokinin B (NKB) as its endogenous agonist. We present here the sequel on the lead optimization of N-acyltriazolopiperazine NK 3 R antagonists (1 and 2, Figure 1 ). 1 NK 3 R antagonists were speculated as therapeutically relevant for CNS dysfunctions, e.g., schizophrenia, predicated on the "hyperdopaminergic hypothesis", which repeatedly met with clinical failures in over a decade of efforts. 2 Meanwhile, emerging biology has unambiguously established the role of NK 3 R/NKB signaling in reproductive neuroendocrinology. Importantly, recent studies have revealed NK 3 R as a key regulatory component of the hypothalamic−pituitary−gonadal (HPG) axis wherein its tonic activation positively regulates the gonadotropin-releasing hormone (GnRH) pulse frequency. 3 In turn, the GnRH pulse frequency is known to differentially control the circulating levels of luteinizing hormone (LH) versus follicle-stimulating hormone (FSH). Thus, high frequency pulses stimulate LH release, whereas low frequency pulses favor FSH induction. 4 These gonadotropins ultimately act on the ovary and testis to promote production of gametes and sex-hormone release. In 2011, it was reported that patients with a loss of function mutation in NK 3 R display a phenotype of normosomic congenital hypogonadotropic hypogonadism, low plasma LH, and attendant low LH/FSH ratios that could be restored through exogenous administration of GnRH. 5 We have demonstrated elsewhere 6 that the foregoing NK 3 R antagonists slow the LH pulse and decrease circulating LH levels without affecting FSH, consistent with the literature reports. 4 As such, these antagonists are subtle modulators of gonadotropin secretion unlike GnRH ligands that abrogate both LH and FSH with the consequent decline in plasma estrogen to castration levels thereby triggering menopausal-like adverse events such as bone mineral density loss and incidences of hot flashes. 7 Hence, NK 3 R antagonists offer a potentially safer therapeutic approach due to a decreased rather than abrogated GnRH pulse frequency. Collectively, these findings offer a strong rationale for repositioning NK 3 R antagonists to address sex-hormones disorders such as polycystic ovary syndrome (PCOS) and uterine fibroids (UF), among others. 8 The synthetic approach to the analogues herein was previously described. 1 With minor modifications, Scheme 1 was used for the GMP scale-up of 3 in overall 42% yield (2.7 kg) with 99.3% purity and >99.9% enantiomeric excess.
The in vitro bioactivity structure−activity relationship (SAR) was established through radioligand binding (pK i ) and aequorin functional assays (pIC 50 ) data from recombinant human NK 3 R in CHO cells. The lead optimization strategy 1 of combined improvement in both bioactivity and ligand lipophilic efficiency (LLE = pK i − logD 7.4 ) 9 was maintained. An initial emphasis was placed on LLE as a predictive marker of improved safety profiles. 10 Other efficiency metrics such as LE 11 and Fsp 3 12 (Table 1) were also tracked, though not as a primary focus. The previously discovered "magic methyl" groups in Rings B and D ( Figure 1 ), 1 so-called due to their significant impact in improving potency and LLE, remained crucial and rendered feasible improvements in Fsp 3 and LE as well (see below).
To recall, replacing 2-methylthiazole (2) at Ring D with 3methyl-1,2,4-thiadiazole (8) was reported earlier to markedly improve bioactivity and LLE ( Table 1 ). 1 Moreover, 1,2,4thiadiazole is regarded as a means of circumventing bioactivation liabilities potentially relevant to the thiazole ring. 13 These considerations overall prompted us to retain the 1,2,4-thiadiazole, but to modify the 4-(thiophen-2-yl)phenyl in 8 to the 4-fluorophenyl Ring A (i.e., 3) present in the earlier lead structures. 1 Progression from 8 to 3 helped reduce lipophilicity (ΔlogD 7.4 = −1.5), which not surprisingly rightshifted bioactivity by nearly one log. However, in evaluating 3 against 8, the improved LLE and absence of the thiophene ring (a potential structural safety alert) 14 was considered of greater importance due to the reduced toxicological risk. In addition, 3 was nearly equipotent to the oral POC lead 2, while >1-log superior in LLE. Narrowing our focus on the thiadiazole Ring D and related variants, we observed the following descending trend in bioactivity (Table 1) : 1,2,4-thiadiazole (3) > 1,2,4oxadiazole (10) ≫ 1,3,4-thiadiazole (9) . As with the Ring A cases, increased lipophilicity in Ring D helped improve bioactivity albeit offset by a loss in LLE, e.g., 11 vs 10 ( Table  1 ). The impact of Rings B and D magic methyl groups on SAR trends was quite pronounced, as expected based on previous results, 1 since the corresponding des-Me analogues of 3, whether at Ring B or D (12 and 13, respectively), were decidedly inferior in both bioactivity and LLE (Table 1) . Gem dimethyl Ring B substitution substantially eroded the bioactivity (14 vs 3) in keeping with the unfavorable impact of (S)-Me at this Ring B position (data not shown). 1 Once again, improved bioactivity followed increased lipophilicity whether at Ring A (15) or at Ring D (16) positions, but this gain was negated by a deteriorated LLE against 3. Conversely, replacing 4-fluorophenyl with phenyl at Ring A, i.e., 17, helped diminish lipophilicity, but it also deteriorated bioactivity.
Interestingly, a hydroxyethyl substitution at Ring B (18) afforded an alternative means of reducing lipophilicity (ΔlogD 7.4 = −0.5 vs 3) with minimal impact on bioactivity, thus resulting in a 0.4-log superior LLE vs 3. Despite this, 18 proved inferior to 3 due to P gp efflux that in turn markedly diminished its brain exposure level ( Table 2 and discussion further below).
The hERG SAR herein (Table 1) was governed by the interplay between lipophilicity and the hydrogen-bond acceptor (HBA) count in the heteroaryl Ring D, as previously reported. 1 For instance, in progressing from 8 to 3 (ΔlogD 7.4 = 1.5), the hERG IC 50 was improved by over 12-fold. However, the poor hERG IC 50 = 1. Based on the free drug hypothesis, the unbound fraction rather than total drug is relevant for PKPD analysis. 15 The NK 3 R is mainly expressed on KNDy neurons in the ARC region of the hypothalamus 3 that is part of the circumventricular organs lacking blood−brain barrier and are therefore exposed to blood solutes. 16 As such, both the unbound plasma ( f u ) and the unbound brain levels (bf u ) must be considered here ( Table 2) . While lipophilicity alone does not correlate well to albumin binding, this trend is often apparent in a congeneric series. 17 Hence, a compound with balanced lipophilicity such as 3 (logD 7.4 = 1.5) displayed high f u and bf u levels (>50%) in contrast to the more lipophilic congeners, e.g., 16 ( Table 2 ). It is noteworthy that despite an increase in unbound plasma concentration, the systemic clearance levels (CL T ) remained low (e.g., 3, Table 2 ). The comparatively lower CL T in para substituted phenyl Ring A (3, 15) against the unsubstituted congener 17 is likely due to the metabolic blocking effect. All analogues except 18 displayed high Caco-2 permeability with no evidence of appreciable P gp efflux (ER = 0.6−1.2), consistent with the high oral availability (%F) and brain-toplasma ratios observed. The so-called P gp rule-of-4 suggests that increasing the number of HBA atoms to (N + O) ≥ 8 tends to confer an increasing likelihood of P gp efflux. 18 This is in keeping with the P gp efflux in 18 (ER = 3.8) given its HBA atom count (N + O = 8). As with 2, 1 a complete oral absorption (%F > 100) was also observed in rat with compound 12 and in monkey with 3. This phenomenon is well-known and various underlying causes have been reported. 19 No drug accumulation was observed in 5-day once-daily oral dosing studies in rats (3 and 12) or monkeys (3), despite administration of elevated doses (e.g., up to 1 g/kg in rats with 12), in step with the relatively short half-life values and the previous related observations with 2. 1 Moreover, no adverse hepatotoxicity (AST, ALT, and bilirubin levels normal) was detected in these subchronic studies. Furthermore, 3 displayed the highest bf u = 0.525 and brain unbound concentration (C brain,u = 343 nM) herein ( Table 2 ). In contrast, 18 although nearly completely unbound in the brain displayed a comparatively low C brain,u = 45.6 nM consistent with its elevated P gp efflux ratio. 
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The key PKPD parameters for interpreting the LH inhibition data are the unbound plasma and brain levels normalized with respect to the bioactivity, i.e., C plasma,u /K i and C brain u /K i (Table  3 ). 1 The plasma and brain levels were determined at the T max for the minimum effective dose (MED). As noted before for 2 and 8, 1 a statistically significant effect was attained at C plasma,u /K i ≥ 7.6 and C brain,u /K i > 1 in rat oral LH inhibition studies. This was also the case here, i.e., for analogues 3, 12, and 16−18, with MED values ranging from 3 mg/kg (3) to 30 mg/kg (12 and 17) . For example, in rats, 3 was 20-fold more efficacious in vivo against the initial POC lead 2 despite being 3-fold right-shifted in K i . This ameliorated efficacy is reflected in their respective MED-normalized plasma and brain PKPD parameters ( Table 3 , the last two columns). Otherwise stated, the >1-log LLE superiority of 3 vs 2 underscores the greater unbound exposure levels and consequently the greater in vivo efficacy of 3. Likewise, the monkey LH data (Figure 2 ) mirrored these trends with 3 4-fold more efficacious (MED levels) although nearly equipotent to 2 in monkey K i values (Table 3) in keeping with the significantly better MED-normalized plasma PKPD parameter for 3 vs 2.
In summary, 3 proved a superior lead candidate based on bioactivity, LLE, LE, and Fsp 3 ( Table 1) criteria. Apart from its excellent hERG and CYP safety profile, 3 was highly efficacious in LH inhibition, showed >2.5-log selectivity against NK 1 R and NK 2 R subtypes, proved >300-fold selective against related HPG axis receptors 1 (KOR, GnRH, GnIH-R, GPR54), and was highly selective in the broad CEREP off-target screen (<25% Table 1 . Human NK 3 R In Vitro Bioactivity, LogD 7.4 , Ligand Efficiency Metrics, 10−12 and Off-Target Safety SAR a N = 3, %RSD ≤ 5. b CYP 3A4, 2D6, 2C9, 2C19, and 1A2, respectively (N = 2, <10% variability). c N = 3, coefficient of variation < 6%.
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Featured Letter inhib at 10 μM). Finally, 3 showed no effect either in Langendorff cardiac safety in rabbits (up to 30 μM) or in AMES genotoxicity test (up to 100 μM). All rat data at 60 min: (B/P) u = C brain,u /C plasma, u with C brain,u = C brain, total × bf u and C plasma,u = C plasma,total × f u . Monkey C plasma,u data at 90 min (oral). b PK formulation: HPβCD. c PK formulation: iv HPβCD; oral 0.5% MC/water. d PK formulation: 1% DMSO, HPβCD in 0.9% NaCl. 
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